Cristina Segú-Vergés

Chief Compliance Officer and Head of Medical Writing Department

Anaxomics (Spain)

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Cristina Segú-Vergés is the Chief Compliance Officer and Head of the Medical Writing Department at Anaxomics in Spain. Her research focuses on the application of in silico modeling to various medical conditions, including Fabry Disease, diabetic macular edema, and COVID-19-related acute respiratory distress syndrome. She has published extensively in the fields of systems biology and artificial intelligence, with a particular emphasis on optimizing treatment strategies and understanding disease pathophysiology.

Articles (8)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Oriol Iborra Egea

Chief Executive Officer

NIMBLE Diagnostics, S.L

SPAIN

View details

Sinisa Savic

Clinical Associate Professor

University of Leeds

UNITED KINGDOM

View details

Jose Manuel Mas

Chief of Scientific Officer

SPAIN

View details

Marta Ferrer

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Cristina Segú-Vergés

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

In Silico Modeling of Fabry Disease Pathophysiology for the Identification of Early Cellular Damage Biomarker Candidates

Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach

Unveiling chronic spontaneous urticaria pathophysiology through systems biology

Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach

Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction

Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach

Collaborators (4)

Oriol Iborra Egea

Sinisa Savic

Jose Manuel Mas

Marta Ferrer

Make your next move.